Document

National Heart, Lung, and Blood Institute; Notice of Meeting

Department of Health and Human Services National Institutes of Health Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a mee...

Department of Health and Human Services
National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Sickle Cell Disease Advisory Committee.

This will be a virtual meeting and will be open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Sickle Cell Disease Advisory Committee.

Date: November 16, 2026.

Time: 12:00 p.m. to 4:00 p.m.

Agenda: Imaging and Clinical Impact on the Eye and Brain in Sickle Cell Disease.

Address: National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20892.

Meeting Link:videocast.nih.gov/​watch/​d8f60236-bb52-11f1-82c0-124f0a52e769.

Meeting Format: Virtual Meeting.

Contact Person: Julie A. Panepinto, MD, MSPH, DFO/Executive Secretary SCDAC, Division of Blood Diseases and Resources, 31 Center Lane, Bethesda, MD 20892, (301) 435-0080, .

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes.

Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: www.nhlbi.nih.gov/​meetings/​index.htm, where an agenda and any additional information for the meeting will be posted when available.

Dated: October 5, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-20617 Filed 10-7-26; 8:45 am]

BILLING CODE 4167-05-P

Legal Citation

Federal Register Citation

Use this for formal legal and research references to the published document.

91 FR 64384

Web Citation

Suggested Web Citation

Use this when citing the archival web version of the document.

“National Heart, Lung, and Blood Institute; Notice of Meeting,” thefederalregister.org (October 8, 2026), https://thefederalregister.org/documents/2026-20617/national-heart-lung-and-blood-institute-notice-of-meeting.